Evidence map›Paper›PMID 37293707›Full record

ArticleDisease models & mechanisms2023

Multiplatform modeling of atrial fibrillation identifies phospholamban as a central regulator of cardiac rhythm.

Anaïs Kervadec, James Kezos, Haibo Ni, Michael Yu, James Marchant, Sean Spiering, Suraj Kannan, Chulan Kwon, Peter Andersen, Rolf Bodmer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Synergistic modelling of human disease.Disease models & mechanisms · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Anaïs KervadecSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
James KezosSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Haibo NiDepartment of Pharmacology, UC Davis, Davis, CA 95616, USA.
Michael YuSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
James MarchantSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Sean SpieringSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Suraj KannanJohns Hopkins University, Baltimore, MD 21205, USA.
Chulan KwonJohns Hopkins University, Baltimore, MD 21205, USA.
Peter AndersenJohns Hopkins University, Baltimore, MD 21205, USA.
Rolf BodmerSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Eleonora GrandiJohns Hopkins University, Baltimore, MD 21205, USA.
Karen OcorrSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2593-0119
Alexandre R ColasSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-8489-0570
Sanford Burnham Prebys Medical Discovery Institute · USJohns Hopkins University · USUniversity of California, Davis · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA · 2019 to 2026
$21.1M
Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
HEART DEVELOPMENT IN DROSOPHILAR01HL054732 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BODMER, ROLF · 1995 to 2024
$11.3M
Development of the Predictive NeuroCardiovascular SimulatorOT2OD026580 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E, GRANDI, ELEONORA · 2018 to 2021
$5.7M
Sex-specific arrhythmogenic mechanisms of atrial fibrillationR01HL131517 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Eleonora Grandi · 2016 to 2026
$5.0M
Defining chromostasis - a candidate regulator of healthy aging and longevityR01AG071464 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ADAMS, PETER D. · 2020 to 2024
$3.9M
Discovery of Small Molecule Promoters of Cardiomyocyte Proliferation to Restore Cardiac Performance in DiseaseR01HL148827 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COLAS, ALEXANDRE ROMAIN · 2019 to 2022
$2.0M
Genetic Pathways in Ceramide-Associated Lipotoxic Cardiomyopathy and Heart FailureR01HL149992 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI BODMER, ROLF · 2020 to 2023
$1.9M
Discovery of small molecule regulators of atrial cardiomyocyte action potential duration to restore normal cardiac rhythm in atrial fibrillationR01HL153645 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COLAS, ALEXANDRE ROMAIN · 2021 to 2024
$1.9M
NCI NIH HHS P30 CA030199NHLBI NIH HHS P01 HL141084NHLBI NIH HHS R01 HL054732NHLBI NIH HHS R01 HL131517NHLBI NIH HHS R01 HL148827NHLBI NIH HHS R01 HL149992NHLBI NIH HHS R01 HL153645NIA NIH HHS R01 AG071464NIGMS NIH HHS T32 GM136577NIH HHS OT2 OD026580
6 · The paper itself

Abstract

Atrial fibrillation (AF) is a common and genetically inheritable form of cardiac arrhythmia; however, it is currently not known how these genetic predispositions contribute to the initiation and/or maintenance of AF-associated phenotypes. One major barrier to progress is the lack of experimental systems to investigate the effects of gene function on rhythm parameters in models with human atrial and whole-organ relevance. Here, we assembled a multi-model platform enabling high-throughput characterization of the effects of gene function on action potential duration and rhythm parameters using human induced pluripotent stem cell-derived atrial-like cardiomyocytes and a Drosophila heart model, and validation of the findings using computational models of human adult atrial myocytes and tissue. As proof of concept, we screened 20 AF-associated genes and identified phospholamban loss of function as a top conserved hit that shortens action potential duration and increases the incidence of arrhythmia phenotypes upon stress. Mechanistically, our study reveals that phospholamban regulates rhythm homeostasis by functionally interacting with L-type Ca2+ channels and NCX. In summary, our study illustrates how a multi-model system approach paves the way for the discovery and molecular delineation of gene regulatory networks controlling atrial rhythm with application to AF.

Indexed as

Atrial FibrillationInduced Pluripotent Stem CellsAdultCalcium-Binding ProteinsHeart AtriaHumansMyocytes, CardiacPhospholambanCalcium-Binding ProteinsPhospholambanAtrial fibrillationCardiac disease modelingComputational modelingDrosophilaHigh-throughput electrophysiologyHuman iPSC-derived atrial-like cardiomyocytesSingle-cell resolution

Identifiers

PMID37293707
PMCPMC10387351
OpenAlexW4379967589

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.